Study on Interleukin-7 (CYT107) in HIV Patients

This was a phase IIa study assessing weekly doses of CYT107 in addition to antiviral treatment (HAART) in adult patients with HIV. CYT107 were administered at the dose of 20 µg/kg based on the patient's weight, in 3 weekly administrations. CYT107 Subcutaneous injection administered at the clinic or day hospital Patients were followed every 3 months for primary and secondary biological activity criteria as well as safety up to 24 months long term follow-up with quarterly visits. A cycle = 3 weekly administrations; D/d0; D/d7; D/d14 For all patients there will be a maximum of 3 cycles over 12 months and a maximum of 4 cycles over 21 months, for a total duration on study of 24 months. All patients were receiving and continued to receive combination antiretroviral therapy while on-study. Pre-medication was not be used systematically but might be administered if needed according to standard clinical practice. During the study visits the following may be done: * Medical history, physical examination, blood tests every visit. * Electrocardiogram (EKG) * Chest x-ray study * Liver/spleen imaging * Blood sample collections at frequent intervals for laboratory tests (Virology: HIV RNA \&HIV DNA;Pharmacodynamics/Immunology;Bacterial translocation ) * Urine tests several times during the study. PBMCs collections for immunological testing An optional substudy on gut biopsy performed prior and at month 3 after the first CYT107 cycle to evaluate T cell homing